The $100M biotech club: Who's in, and what’s it take to join the top-per­form­ing group of bio­phar­mas?

Who doesn’t love da­ta in this busi­ness? For deal­mak­ers and sci­en­tists alike, the proof be­hind any the­o­ry lies in the num­bers. And we have an­oth­er telling break­down of the num­bers for you to­day.

This third in­stall­ment on deal­mak­ing trends from Deal­For­ma’s Chris Doko­ma­ji­lar is based on a data­base in­volv­ing 6,681 de­vel­op­ment deals that were struck be­tween Jan­u­ary 1, 2008 and to­day. He found more than 150 that qual­i­fied for the $100 mil­lion club, in­volv­ing cash and eq­ui­ty pay­ments that met the bar for a 9-fig­ure cash deal.

These high-end deals ac­count­ed for more than $40 bil­lion in cash, $31 bil­lion if you’re look­ing at just the cash up­front mi­nus any eq­ui­ty stake. It’s a key por­tion of the to­tal amount that’s been in­vest­ed in the in­dus­try over the past decade. And 16 of them have been writ­ten off as losers.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER